ISSN2456-3315
Impact Factor10.57
UGC CAREApproved
Low Cost₹599 / $45
CrossRefDOI
ESTD2016
Peer ReviewTransparent
AccessOpen
Submission: Always Open
Paper Title
Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis
Authors
Taseem A. Mokhdomi , Shoiab Bukhari , Asif Amin , Qazi Danish , Sajad H. Wani
Keywords
FGFR-2; Tyrosine Kinase Inhibitors; Pazopanib; Emodin; Molecular Docking Simulation.
Abstract
Fibroblast growth factor receptor-2 (FGFR-2) primarily regulating mitogenesis and differentiation, is considered as a major prognostic biomarker as well as a therapeutic target in human solid tumors. Most of the therapeutic drugs have been designed to target its catalytic domain which inhibit tyrosine phosphorylation of its kinase domain and hence block its downstream signaling. In this study, we analyzed selected drug-leads from western himalayan chemiome for their ability to bind and selectively inhibit FGFR-2 activation. Structure based bioinformatics were employed to select lead compound(s) targeting catalytic domain of FGFR-2. Out of 120 compounds from selective western himalayan chemiome library, Emodin showed best binding-affinity with catalytic domain of FGFR-2 blocking ATP binding. The binding efficiency of Emodin was comparable to Pazopanib, FDA approved Tyrosine Kinase Inhibitor which is a potent and selective inhibitor of FGFR-2 currently in clinical trials. To further corroborate these findings, we evaluated binding efficiency of Emodin in 2 constitutively active mutants of FGFR-2 viz N549T and E565A. Emodin efficiently blocked ATP pocket in their respective catalytic domain comparable to Pazopanib. The results in this study thus not only project Emodin as a lead molecule to overcome FGFR-2 mediated tumor mitogenesis but also demonstrates its potential as a tyrosine kinase inhibitor to overcome tumor angiogenesis.
Full Paper, Downloads & Preview
How To Cite
Choose the style your journal or department asks for, then copy it. Every version below is generated from this paper's own record.
IJRTI — journal style
"Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis", IJRTI - International Journal for Research Trends and Innovation (www.ijrti.org), ISSN:2456-3315, Vol.2, Issue 12, page no.14 - 17, December-2017, Available :https://ijrti.org/papers/IJRTI1712003.pdf
APA — 7th edition
Mokhdomi, T. A., Bukhari, S., Amin, A., Danish, Q., & Wani, S. H. (2017). Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis. International Journal for Research Trends and Innovation, 2(12), 14 - 17. https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003
MLA — 9th edition
Mokhdomi, Taseem A., et al. "Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis." International Journal for Research Trends and Innovation, vol. 2, no. 12, 2017, pp. 14 - 17, https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003.
Chicago — 17th, bibliography
Mokhdomi, Taseem A., et al. "Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis." International Journal for Research Trends and Innovation 2, no. 12 (2017): 14 - 17. https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003.
Harvard — author–date
Mokhdomi, T.A. et al. (2017) 'Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis', International Journal for Research Trends and Innovation, 2(12), pp. 14 - 17. Available at: https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003
IEEE — numbered reference
T. A. Mokhdomi, S. Bukhari, A. Amin, Q. Danish and S. H. Wani, "Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis," IJRTI, vol. 2, no. 12, pp. 14 - 17, Dec. 2017.
Vancouver — biomedical
Mokhdomi TA, Bukhari S, Amin A, Danish Q, Wani SH. Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis. IJRTI. 2017 Dec;2(12):14 - 17.
AMA — 11th edition
Mokhdomi TA, Bukhari S, Amin A, Danish Q, Wani SH. Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis. IJRTI. 2017;2(12):14 - 17. Accessed at https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003
BibTeX — Zotero, Mendeley, LaTeX
@article{IJRTI1712003,
author = {Taseem A. Mokhdomi and Shoiab Bukhari and Asif Amin and Qazi Danish and Sajad H. Wani},
title = {Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis},
journal = {International Journal for Research Trends and Innovation},
volume = {2},
number = {12},
pages = {14 - 17},
year = {2017},
month = {December},
issn = {2456-3315},
url = {https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003}
}
RIS — EndNote, RefWorks
TY - JOUR
AU - Mokhdomi, Taseem A.
AU - Bukhari, Shoiab
AU - Amin, Asif
AU - Danish, Qazi
AU - Wani, Sajad H.
TI - Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis
T2 - International Journal for Research Trends and Innovation
JA - IJRTI
VL - 2
IS - 12
PY - 2017
SN - 2456-3315
UR - https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003
SP - 14
EP - 17
ER -
Issue
Volume 2 Issue 12,
December-2017
Pages : 14 - 17
Other Publication Details
Paper Reg. ID
IJRTI_170589
Published Paper ID
IJRTI1712003
Downloads
205,636
Research Area
Biological Science
Country
Srinagar, Jammu & Kashmir, India
Published
December 2017
Published Paper PDF
https://ijrti.org/papers/IJRTI1712003.pdf
Published Paper URL
https://ijrti.org/viewpaperforall.php?paper=IJRTI1712003
About Publisher
International Journal for Research Trends and Innovation
Published by IJRTI (JW Publication)
2456-3315
ISSN
10.57
Impact Factor
2016
ESTD Year
Open
Access
Impact Factor 10.57 calculated by Google Scholar and Semantic Scholar.
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 10.57 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
UGC CARE Approved Journal — Transparent Peer-reviewed journal aligned with UGC’s 2025 suggestive parameters, with CrossRef DOI registration and Scopus Standard metadata on every published paper.
Licence
© 2017 — Authors hold the copyright of this article.
This work is licensed under a
Creative Commons Attribution 4.0 International License
and The Open Definition.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Disclaimer:
The content, data and findings in this article are based on the authors’ research and have been
peer-reviewed for academic purposes only. Readers are advised to verify all information before practical
or commercial use. The journal and its editorial board are not liable for any errors, losses or
consequences arising from its use.
Declarations
Funding
No external funding was received for this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Acknowledgements
The authors would like to thank the reviewers and the editorial board of International Journal for Research Trends and Innovation for their careful reading and constructive comments, and all colleagues who supported the preparation of this manuscript.
